2020
DOI: 10.1111/bph.15016
|View full text |Cite
|
Sign up to set email alerts
|

Current and future treatments of pulmonary arterial hypertension

Abstract: Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin, and NO pathways has significantly improved outcomes. However, for the vast majority of patients, PAH remains a life-limiting illness with no prospect of cure.PAH is characterised by pulmonary vascular remodelling. Current research focusses on targeting the underlying pathways of aberrant proliferation, migration, and apoptosis. Despi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
123
0
3

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 126 publications
(127 citation statements)
references
References 159 publications
(266 reference statements)
1
123
0
3
Order By: Relevance
“…Recent efforts have focused on exploiting the multiple mechanisms leading to pulmonary vascular remodeling seen in PAH to develop novel therapeutics. Various pathways for target include suppressing inflammation and modulating the immune response, altering oxidant stress mechanisms, restoring the balance between pro-proliferative and antiproliferative signaling, and targeting growth factor signaling pathways pertinent to BMPR2 regulation [101,103,104].…”
Section: Future Directions In Pulmonary Arterial Hypertension Managementmentioning
confidence: 99%
“…Recent efforts have focused on exploiting the multiple mechanisms leading to pulmonary vascular remodeling seen in PAH to develop novel therapeutics. Various pathways for target include suppressing inflammation and modulating the immune response, altering oxidant stress mechanisms, restoring the balance between pro-proliferative and antiproliferative signaling, and targeting growth factor signaling pathways pertinent to BMPR2 regulation [101,103,104].…”
Section: Future Directions In Pulmonary Arterial Hypertension Managementmentioning
confidence: 99%
“…Experimental studies using hypoxia-induced pulmonary hypertension models help in identifying new targets for development of novel drugs, including growth factors, transcription factors, and inflammation and metabolic remodeling [337].…”
Section: Novel Potential Therapeutic Targetsmentioning
confidence: 99%
“…2Ac). PDGF-BBmediated increases in pPDGFRa, pPDGFRb, and pAKT (at S473 and T308) were significantly inhibited in both normal and IPAH PASMC pre-incubated with a low dose (0.3-1 mM) of pharmacological blocker of PDGFR, imatinib, 20,34 a TKR blocker, for 30 min (Fig. 2Aa and b); the imatinib-mediated inhibition of pAKT at S473 seemed to be greater in IPAH-PASMC than in normal PASMC (Fig.…”
Section: Increased Activation Of Pdgfra and Pdgfrb In Pasmc From Patimentioning
confidence: 93%